top of page
Banner-Back.jpg

BOLT-360™ Platform

Creating modular, single-chain, bispecific antibodies

Inside-Bolt-Bispecific.png
Platform Highlights

Smart design. Meaningful results.

  • Hybrid binders with multiple functions

  • Tunable linkers enabling precise activation

  • Rapid discovery and design iterations

  • Data-driven engineering for safety and durability

The Process

We combine precision design with rapid iteration-creating antibodies that are potent, selective, and built for safety.

Design-Sciences-Blue.png

design

Safety-Sciences2.png

screen

Validate-Sciences3.jpg

validate

Validating the Science

VALIDATE

Ensuring Safety for the Science

SCREEN

Designing the Science

DESIGN

Why Ajaya is Different

PROPRIETARY

Selectively eliminates disease- driving immune cells

Powerful

>90% depletion seen in preclinical screens

Precise

Lowers inflammation, avoids hidden resistance, minimizes off-target risks

Robust

Built on a well-studied target with strong safety rationale

Ajaya Pipeline

Our Pipeline

Ajaya is advancing a pipeline of differentiated therapeutics beginning with refractory rheumatoid arthritis (RA), where 1 in 6 patients fail current broad-spectrum treatments, proving the unparalleled selectivity of our platform.

Our Pipeline

Ajaya is advancing a pipeline of differentiated therapeutics beginning with refractory rheumatoid arthritis (RA), where 1 in 6 patients fail current broad-spectrum treatments, proving the unparalleled selectivity of our platform.

Ajaya Pipeline
ContactUs-Background.jpg

Let's Talk

Interested in learning more about our science?

Images/drawings created using Biorender

bottom of page